Medical Industry Feature

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. © Eisai Inc. 2024. All Rights Reserved.AD-M2130 November 2024

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293. © Eisai Inc. 2024. All Rights Reserved.AD-M2123 November 2024

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Guest: Scott Gottlieb, MD Host: Charles Turck, PharmD, BCPS, BCCCP Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.

Unknown: Arnold Advincula, MD With over 20 years of experience performing the transabdominal cerclage, Dr. Arnold Advincula, Chief of Gynecologic Specialty Surgery at NewYork-Presbyterian and Columbia, has a deep expertise in helping women with cervical insufficiency achieve successful pregnancies. Through the expanded use of robotics, Dr. Advincula and his team are completing the procedure minimally invasively and with more accuracy and precision. Watch to learn how this advanced technique is transforming gynecologic surgery by reducing recovery time and helping women reach their reproductive goals. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Shizuko Morimoto, PsyD Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City. Reference: American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model Dr. Morimoto is a paid consultant of Otsuka. November 2024 US.UNB.X.24.00100

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Steven Maron, MD, MSc Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York. References: The Cancer Genome Atlas Network. Nature. 2014;513:202-209. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082. ©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Robert McCarron, MD Guest: Arwen Podesta, MD Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That’s why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association. Drs. McCarron and Podesta are consultants for Otsuka. September 2024 US.UNB.X.24.00073

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha. Dr. Emerson is a paid consultant of Otsuka. September 2024 US.UNB.X.24.00082

Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics …

Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage …

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine. References: Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/. Agios Pharmaceuticals, Inc. © 2024 All right reserved.SCD-US-0095 / June 2024

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jessie Hsieh, MD Guest: David Isaacson, MD About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with MCED testing and a real-world patient case are Drs. Jesse Hsieh and David Isaacson. Dr. Hsieh is the Chairman of the Board of Beacon Health System in Indiana, and Dr. Isaacson is an Assistant Professor of Otolaryngology at the Indiana University School of Medicine. Reference: Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at: http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA-2021-0065

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Leigh Anne Cantrell, MD, MSPH The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology. COBAS and CINTEC are trademarks of Roche. All other product names and trademarks are the property of their respective owners. 07/24

Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.Sage Therapeutics, Inc. All rights reserved.Sage Therapeutics ©2024 MRC-PPD-00792 06/2024

Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc Guest: Dru Riddle, PhD, DNP, CRNA When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an antiemetic should be administered from a different class from what's given for prevention.1 Barhemsys® (amisulpride) is an FDA-approved antiemetic for the treatment of PONV in patients who have or have not received prophylaxis.2 Learn more about this treatment option along with current management guidelines, key clinical considerations, and a real-world case study with TJ Gan, MD, MBA, MHS, and Dru Riddle, PhD, DNP. Dr. Gan is the Head of the Division of Anesthesiology and Perioperative Medicine, Critical Care, and Pain Medicine at the University of Texas MD Anderson Cancer Center in Houston, and Dr. Riddle is a certified nurse anesthetist at Texas Christian University in Ft. Worth, TX.

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42. ©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.US-NONO-00581 05/2024

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health. REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.© 2024 Bristol-Myers Squibb Company2007-US-2300376 03/24

Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children’s Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-FCV-24-0055 08/24